SCHEMBL1471709

SCHEMBL1471709

O=C1C=C(c2ccccc2)C(=O)N1c1cc(Cl)cc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
NPSR1 Q6W5P4 4/20 0.47
MAPT P10636 4/20 0.47
ALOX12 P18054 3/20 0.47
HPGD P15428 2/20 0.47
CACNA1B Q00975 2/20 0.47
APBA1 Q02410 2/20 0.47
LMNA P02545 2/20 0.47
HSP90AA1 P07900 2/20 0.47
HCRTR1 O43613 1/20 0.47
S1PR4 O95977 1/20 0.47
S1PR1 P21453 1/20 0.47
GAA P10253 3/20 0.45
CCR6 P51684 2/20 0.45
ITGA4 P13612 1/20 0.41
ITGB7 P26010 1/20 0.41
HTT P42858 2/20 0.40
RGS4 P49798 1/20 0.40
PTPRC P08575 1/20 0.38
RAD51 Q06609 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL934144 0.87 MGLL (0.53) ALDH1A1NPSR1MAPTALOX12HPGD
SCHEMBL1471657 0.87 MAPT (0.54) ALDH1A1NPSR1MAPTALOX12HPGD
SCHEMBL303331 0.84 ALDH1A1 (0.51) ALDH1A1NPSR1MAPTALOX12HPGD
SCHEMBL1473349 0.83 MAPT (0.57) ALDH1A1NPSR1MAPTALOX12HPGD
SCHEMBL1471293 0.83 ALDH1A1 (0.49) ALDH1A1NPSR1MAPTALOX12HPGD
SCHEMBL1473725 0.83 RAD51 (0.46) ALDH1A1NPSR1MAPTALOX12HPGD
SCHEMBL1471248 0.83 RAD51 (0.58) ALDH1A1NPSR1MAPTALOX12HPGD
SCHEMBL1471763 0.81 ALDH1A1 (0.43) ALDH1A1NPSR1MAPTALOX12HPGD
SCHEMBL1473521 0.81 PTPRC (0.42) ALDH1A1MAPTALOX12GAAITGA4
SCHEMBL1471600 0.79 ESR2 (0.45) ALDH1A1NPSR1MAPTALOX12HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7915304-B2 Phenyl substituted maleimides as medicaments for blocking degenerative tissue damages by inhibiting MPT CONGENIA S.R.L. (IT) 2011-03-29 US disclosed
EP-2091531-B1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S R L (IT) 2010-11-24 EP disclosed
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2010-04-22 US disclosed
EP-2091531-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT Congenia S.r.l. (IT) 2009-08-26 EP disclosed
WO-2008067863-A2 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CONGENIA S.R.L. (IT) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099736-A1 PHENYL SUBSTITUTED MALEIMIDES AS MEDICAMENTS FOR BLOCKING DEGENERATIVE TISSUE DAMAGES BY INHIBITING MPT CYC1, MTPN, TXN2 ALDH1A1 800/4885NPSR1 2341/4885MAPT 1947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.